Subscribe

Risk Factors for Bleeding in a Patient Receiving Dasatinib Therapy for Chronic Myelogenous Leukemia (CML)

Specialty:

Hematology Oncology

Objective:

ICD-10:

Description:

Quintas-Cardama et al identified risk factors associated with dasatinib therapy to a patient with chronic myelogenous leukemia (CML). Dasatinib is a tyrosine kinase inhibitor that is used when the patient is resistant to or intolerant of imatinib mesylate. The authors are from the University of Texas M.D. Anderson Cancer Center in Houston.

To read more or access our algorithms and calculators, please log in or register.

RECENT TWEETS

medal descover
medal iphone